Gt biopharma reports second quarter 2023 financial results

C ash of approximately $ 1 8.0 million as of june 30 , 202 3 , provide s ample runway to fund operations into q 3 202 4; anticipated to b e sufficient to achieve ind clearance for gtb-3650 and initiate clinical trial activit ies on gtb-3650.
GTBP Ratings Summary
GTBP Quant Ranking